Search results

1656 results

Sorted by Relevance . Sort by Date

  1. Caesarean section (update)

    In development [GID-NG10081] Expected publication date: 31 March 2021

  2. Inducing labour (update)

    In development [GID-NG10082] Expected publication date: 14 October 2021

  3. Acne Vulgaris: Management

    In development [GID-NG10109] Expected publication date: 09 June 2021

  4. Pernicious anaemia

    In development [GID-NG10176] Expected publication date: TBC

  5. Diabetes update

    In development [GID-NG10152] Expected publication date: TBC

  6. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults

  7. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults

  8. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults

  9. Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a

  10. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

    Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy